Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406458 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
A Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 15
- Study locations
NCT00406458 is a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Sangamo Therapeutics. The registered enrollment target is 110 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT00406458, a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
Conditions Studied
Interventions
- OTHER Normal Saline
- DRUG SB-509
Study Locations (15)
California
- Coordinated Clinical Research - La Jolla
- Advanced Medical Research, LLC - Lakewood
- SF Clinical Research Center - San Francisco
- Diablo Clinical Research - Walnut Creek
Florida
- Bradenton Research Center - Bradenton
- University of Miami, Diabetes Research Institute - Miami
- Neurology Clinical Research - Sunrise
New York
- Upstate Clinical Research - Albany
- Peripheral Neuropathy Center, Weill Medical College of Cornell University - New York
Texas
- Nerve and Muscle Center of Texas - Houston
- DGD Research - San Antonio
Kansas
- University of Kansas Medical Center - Kansas City
Nebraska
- Creighton Diabetes Center - Omaha
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Col. Roma
- Instituto Mexicano de Investigación Clinica - Mexico City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406458
The ClinicalTrials.gov registry entry for NCT00406458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT00406458 reports 15 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00406458 about?
NCT00406458 is a clinical study titled "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy". The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
What is the current status of trial NCT00406458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2006-11. Estimated completion is 2009-05.
What conditions does trial NCT00406458 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetic Polyneuropathy.
What interventions are being tested in trial NCT00406458?
The interventions under investigation include: Normal Saline (OTHER), SB-509 (DRUG).
Who is sponsoring clinical trial NCT00406458?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406458 being conducted?
This trial has 15 study locations across California, Florida, Kansas, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.